Hematopoietic Stem Cell TransplantationPeripheral Blood Stem Cell TransplantationTransplantation, HomologousTransplantation, AutologousGraft vs Host DiseaseTransplantation ConditioningStem Cell TransplantationBone Marrow TransplantationHematologic NeoplasmsHematopoietic Stem Cell MobilizationBusulfanTreatment OutcomeTissue DonorsStem CellsImmunosuppressive AgentsTransplantation ChimeraHematopoietic Stem CellsMyeloablative AgonistsGraft SurvivalGranulocyte Colony-Stimulating FactorCytomegalovirus InfectionsLeukapheresisVidarabineAntigens, CD34RecurrenceHistocompatibility TestingRetrospective StudiesCombined Modality TherapyMultiple MyelomaMelphalanRemission InductionWhole-Body IrradiationGraft vs Leukemia EffectCord Blood Stem Cell TransplantationCyclophosphamideHistocompatibilityBlood Component RemovalGraft vs Tumor EffectLeukemiaAntineoplastic Combined Chemotherapy ProtocolsSalvage TherapyLymphocyte TransfusionDisease-Free SurvivalLeukemia, Myeloid, AcuteSurvival AnalysisSurvival RateTime FactorsLymphocyte DepletionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSiblingsLymphoma, Non-HodgkinMyelodysplastic SyndromesImmunocompromised HostAntilymphocyte SerumKidney TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaCytomegalovirusAnemia, AplasticTransplantationT-LymphocytesAntiviral AgentsChimerismHematologic DiseasesOpportunistic InfectionsNeoplasm, ResidualAcute DiseaseCyclosporineHematopoiesisFollow-Up StudiesInfectionTransplantation ImmunologyHLA AntigensEtoposideEmbryonic Stem CellsBlood CellsImmunosuppressionMinor Histocompatibility AntigensVirus ActivationHodgkin DiseaseHepatic Veno-Occlusive DiseaseCytarabineGraft RejectionFlow CytometryMesenchymal Stem Cell TransplantationAdult Stem CellsBone Marrow CellsBlood DonorsFatal OutcomeAntineoplastic AgentsRoseolovirus InfectionsPrognosisLeukocyte TransfusionBlood Cell CountCell DifferentiationLymphomaGanciclovirAntineoplastic Agents, AlkylatingLeukemia, MyeloidTransplantation, IsogeneicThiotepa